FY2025 · ended Dec 31, 2025 · Revenue $5.34B, +40.2% YoY · Filed Feb 26, 2026
Beone Medicines Ltd. (ONC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5.3 billion and net income of $286.9 million. Free cash flow was $941.7 million. As of Sep 30, 2026 it held $5.8 billion in cash and investments and $1.3 billion in total debt.
Revenue (TTM)
$6.61B
+32.9% vs year-ago TTM
Net income (TTM)
$915.57M
+1235.6% vs year-ago TTM
Operating cash flow (TTM)
$1.59B
+102.5% vs year-ago TTM
Free cash flow (TTM)
$1.45B
+166.1% vs year-ago TTM
EPS (TTM)
$0.61
+1180.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.44B
+4.0% vs prior year
Net cash
$4.57B
as of Sep 30, 2026
Operating margin
17.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONC (Nasdaq), BEIGF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Basel
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1651308
- Former names
- BeiGene, Ltd. (until May 27, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.3B | $3.8B | $2.5B | $1.4B | $1.2B |
| Operating income | $447.1M | -$568.2M | -$1.2B | -$1.8B | -$1.4B |
| Net income | $286.9M | -$644.8M | -$881.7M | -$2.0B | -$1.5B |
| Diluted EPS | $0.19 | -$0.47 | -$0.65 | -$1.49 | -$1.21 |
| Operating cash flow | $1.1B | -$140.6M | -$1.2B | -$1.5B | -$1.3B |
| Free cash flow | $941.7M | -$633.3M | -$1.7B | -$1.8B | -$1.6B |
| Total assets | $8.2B | $5.9B | $5.8B | $6.4B | $8.5B |
| Total liabilities | $3.8B | $2.6B | $2.3B | $2.0B | $2.4B |
| Stockholders' equity | $4.4B | $3.3B | $3.5B | $4.4B | $6.1B |
| Cash and investments | $4.6B | $2.8B | $3.3B | $4.6B | $6.7B |
| Total debt | $1.1B | $1.1B | $930.2M | $596.7M | $694.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 26, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
Jun 26, 2026 | Jun 26, 2026 |
All 1002 Beone Medicines Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.